Soluble Fas in malignant pleural effusion and its expression in lung cancer cells
-
- MITANI Kayo
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- NISHIOKA Yasuhiko
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- YAMABE Kazue
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- OGAWA Hirohisa
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- MIKI Toyokazu
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- YAMAGAWA Hiroaki
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- SONE Saburo
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
Search this Article
Author(s)
-
- MITANI Kayo
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- NISHIOKA Yasuhiko
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- YAMABE Kazue
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- OGAWA Hirohisa
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- MIKI Toyokazu
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- YAMAGAWA Hiroaki
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
-
- SONE Saburo
- Department of Internal Medicine and Molecular Therapeutics, Course of Medical Oncology, University of Tokushima School of Medicine
Journal
-
- Cancer science
-
Cancer science 94(3), 302-307, 2003-03-31
References: 37
-
1
- Fas and Fas ligand : a death factor and its receptor
-
NAGATA S.
Adv Immunol 57, 129-144, 1994
Cited by (1)
-
2
- The role of Fas/Fasl in immunosuppression induced by human tumors
-
WHITESIDE TL
Cancer Immunol Immunother 46, 175-184, 1998
Cited by (1)
-
3
- Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
-
CASCINO I
J Immunol 154, 2706-2713, 1995
Cited by (4)
-
4
- An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro
-
PAPOFF G
J Immunol 156, 4622-4630, 1996
Cited by (3)
-
5
- Elevated soluble Fas (sFas) levels in Nonhematopoietic human malignancy
-
MIDIS GP
Cancer Res 56, 3870-3874, 1996
Cited by (3)
-
6
- Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias
-
KNIPPING E
Blood 85, 1562-1569, 1995
Cited by (1)
-
7
- Prognostic significance of soluble Fas in the serum of patients with bladder cancer
-
MIZUTANI Y
J Urol 160, 571-576, 1998
Cited by (2)
-
8
- Soluble Fas in the serum of patients with non-Hodgkin's lymphoma : higher concentrations in angioimmunoblastic T-cell lymphoma
-
YUFU Y
Am J Hematol 58, 334-336, 1998
Cited by (1)
-
9
- Circulating soluble Fas concentration in breast cancer patients
-
UENO T
Clin Cancer Res 5, 3529-3533, 1999
Cited by (1)
-
10
- Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies
-
KONNO R
Clin Cancer Res 6, 3576-3580, 2000
Cited by (2)
-
11
- Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients
-
UGUREL S
Clin Cancer Res 7, 1282-1286, 2001
Cited by (1)
-
12
- Spontaneous production of interleukin-8 by human lung cancer cells and its augmentation by tumor necrosis factor alpha and interleukin-1 at protein and mRNA levels
-
MIZUNO K
Oncology 51, 467-471, 1994
Cited by (1)
-
13
- Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice
-
MIKI T
Oncol Res 12, 209-217, 2000
Cited by (4)
-
14
- Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens
-
YONEI T
Acta Med Okayama 47, 233-241, 1993
Cited by (1)
-
15
- Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer
-
YANAGAWA H
Cancer Immunol Immunother 48, 396-400, 1999
Cited by (3)
-
16
- Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction : the possibility of immunological overcoming of multidrug resistance
-
NISHIOKA Y
Int J Cancer 71, 170-177, 1997
Cited by (2)
-
17
- Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced : a preliminary report
-
HELLQUIST HB
Br J Cancer 76, 175-179, 1997
Cited by (1)
-
18
- DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement
-
OWEN-SCHAUB LB
Cell Immunol 140, 197-205, 1992
Cited by (2)
-
19
- Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
-
LEITHAUSER F
Lab Invest 69, 415-429, 1993
Cited by (5)
-
20
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
-
ITOH N.
Cell 66, 233-243, 1991
DOI Cited by (157)
-
21
- Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
-
OEHM A.
J Biol Chem 267, 10709-10715, 1992
Cited by (16)
-
22
- The Fas death factor
-
NAGATA S.
Science 267, 1449-1456, 1995
DOI Cited by (169)
-
23
- Apoptosis by death factor
-
NAGATA S.
Cell 88, 355-365, 1997
DOI Cited by (212)
-
24
- Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
-
KAGI D.
Science 265, 528-530, 1994
DOI Cited by (62)
-
25
- Fas-mediated cytotoxicity by freshly isolated natural killer cells
-
ARASE H.
J Exp Med 181, 1235-1238, 1995
DOI Cited by (18)
-
26
- I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
-
HU S.
J Biol Chem 272, 17255-17257, 1997
DOI Cited by (8)
-
27
- Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
-
CHENG J.
Science 263, 1759-1762, 1994
DOI Cited by (52)
-
28
- Soluble Fas/APO-1 in tumor cells : a potential regulator of apoptosis?
-
OWEN-SCHAUB LB
Cancer Lett 94, 1-8, 1995
DOI Cited by (2)
-
29
- Human hepatocytes produce an isoform of Fas that inhibits apoptosis
-
KRAMS SM
Transplantation 65, 713-721, 1998
DOI Cited by (3)
-
30
- Increased serum levels of soluble Fas in progressive B-CLL
-
OSORIO LM
Eur J Haematol 66, 342-346, 2001
DOI Cited by (1)
-
31
- Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
-
JUDO S
Clin Exp Immunol 112, 166-171, 1998
DOI Cited by (3)
-
32
- Discrepant expression of membrane and soluble isoform of Fas (CD95/APO-1) in adult T-cell leukemia : soluble Fas isoform is an independent risk factor for prognosis
-
KAMIHARA S
Br J Haematol 107, 851-860, 1999
DOI Cited by (6)
-
33
- Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
-
KIMURA M
Br J Cancer 80, 1648-1651, 1999
DOI Cited by (2)
-
34
- Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells
-
NISHIMURA N
Hum Gene Ther 12, 333-346, 2001
DOI Cited by (1)
-
35
- Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas
-
NAMBU Y.
J Clin Invest 101, 1102-1110, 1998
DOI Cited by (2)
-
36
- Analysis of Fas and Fas ligand expression and function in lung cancer cell lines
-
KAWASAKI M
Eur J Cancer 36, 656-663, 2000
DOI Cited by (1)
-
37
- Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer
-
YANAGAWA H
Lung Cancer 27, 67-73, 2000
DOI Cited by (2)